In a report released today, Laura Sutcliffe from UBS maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a ...

ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

Telix Pharmaceuticals Limited today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx ...

Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...

Liberation Day did not deliver punitive tariffs on the pharmaceutical sector - but the reprieve could be short lived.

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

As we expected, no-moat Telix’s slightly updated product, Gozellix, has received US regulatory approval. Like Illuccix, which contributes practically all of Telix’s current revenue ...

MELBOURNE, Australia, April 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase ...